Abstract

Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England

J Med Econ. 2024 Feb 23:1-19. doi: 10.1080/13696998.2024.2313932. Online ahead of print

Tariq H Iqbal 1Nicholas Kennedy 2Anjan Dhar 3 4Waqas Ahmed 5Richard F Pollock 5

 
     

Author information

1Queen Elizabeth Hospital Birmingham, Birmingham, UK.

2Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.

3Department of Gastroenterology, County Durham & Darlington NHS Foundation Trust, Durham, UK.

4School of Health and Life Sciences, Teesside University, Teesside, UK.

5Covalence Research Ltd, Harpenden, UK.

Abstract

Aims: Anemia is the most common extraintestinal complication of inflammatory bowel disease (IBD), with approximately half of cases caused by iron deficiency (ID). Intravenous iron is the preferred ID anemia (IDA) treatment where oral iron is contraindicated, ineffective or not tolerated, or where ID correction is urgent. The objective was to evaluate the cost-utility of ferric derisomaltose (FDI) versus ferric carboxymaltose (FCM) in patients with IBD and IDA in England, in whom IV iron treatment is preferred.

Materials and methods: A patient-level simulation model was developed, capturing quality of life (QoL) differences based on SF-36v2 data from the PHOSPHARE-IBD randomized controlled trial, monitoring and incidence of post-infusion hypophosphatemia, and number of iron infusions required. Analyses were conducted over a five-year time horizon from the Department of Health and Social Care (DHSC) perspective, with healthcare provider and societal perspectives adopted in separate micro-costing analyses. Future costs and effects were discounted at 3.5% per annum and one-way and probabilistic sensitivity analyses were performed.

Results: FDI increased quality-adjusted life expectancy by 0.075 QALYs versus FCM from 2.57 QALYs to 2.65 QALYs per patient. Patients receiving FDI required 1.63 fewer iron infusions over the five-year time horizon, driving infusion-related cost savings of GBP 496 per patient (GBP 2,188 versus GBP 1,692) from the DHSC perspective. Costs of monitoring and treating hypophosphatemia after FCM were GBP 226, yielding total savings of GBP 722 per patient (GBP 2,414 versus GBP 1,692) over the five-year time horizon. FDI also led to reduced costs versus FCM in the societal and provider micro-costing analyses and was therefore the dominant intervention across all three perspectives.

Limitations: The analysis did not capture patient adherence, hypophosphatemic osteomalacia, or fractures.

Conclusions: Results showed that FDI improved patient QoL and reduced direct healthcare expenditure versus FCM in patients with IBD and IDA in England.

© Copyright 2013-2024 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.